REDWOOD CITY, Calif.,
Aug. 2, 2013 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that it will release
second quarter 2013 financial results after market close on
Monday, August 12, 2013. AcelRx
management will host an investment-community conference call at
4:30 p.m. eastern time (1:30 p.m. pacific time) on August 12, 2013 to discuss the financial results
and provide a corporate update.
Investors who wish to participate in the conference call may do
so by dialing (800) 860-2442 for domestic callers, (866) 605-3852
for Canadian callers or (412) 858-4600 for international callers.
Those interested in listening to the conference call live via the
internet may do so by visiting the Investors page of the company's
website at www.acelrx.com and clicking on the webcast link on the
Investors home page.
A webcast replay will be available on the AcelRx website for 90
days following the call by visiting the Investor page of the
company's website at www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, Zalviso, is designed
to solve the problems associated with post-operative intravenous
patient-controlled analgesia which has been shown to cause harm to
patients following surgery because of the side effects of morphine,
the invasive IV route of delivery and the complexity of infusion
pumps. AcelRx has announced positive results from each of the
three Phase 3 clinical trials for Zalviso and AcelRx anticipates
submitting a New Drug Application with the FDA in the third quarter
of 2013. AcelRx also announced positive top-line results for a
Phase 2 trial for ARX-04, a sufentanil formulation for the
treatment of moderate-to-severe acute pain, funded through a grant
from U.S. Army Medical Research and Materiel Command. The
company has two additional pain treatment product candidates,
ARX-02 and ARX-03, which have completed Phase 2 clinical
development. For additional information about AcelRx's
clinical programs, please visit www.acelrx.com.
Forward Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to anticipated
timing of submission of the NDA and the therapeutic potential of
AcelRx Pharmaceuticals' product candidates. These forward-looking
statements are based on AcelRx Pharmaceuticals' current
expectations and inherently involve significant risks and
uncertainties. AcelRx Pharmaceuticals' actual results and the
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to:
AcelRx Pharmaceuticals' ability to submit an NDA and receive
regulatory approval for Zalviso, that fact that FDA may dispute or
interpret differently positive clinical results obtained to date;
any delays or inability to obtain and maintain regulatory approval
of its product candidates, including Zalviso, in the United States and Europe; its ability to attract funding
partners or collaborators with development, regulatory and
commercialization expertise; its ability to obtain sufficient
financing to commercialize Zalviso; the market potential for
its product candidates; and other risks detailed in the "Risk
Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities
and Exchange Commission filings, including its Current Report on
Form 8-K filed with the SEC on July
19, 2013. AcelRx Pharmaceuticals undertakes no duty or
obligation to update any forward-looking statements contained in
this release as a result of new information, future events or
changes in its expectations.
(Logo:
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)
SOURCE AcelRx Pharmaceuticals, Inc.